MVP and lung adenocarcinoma: The role of YB-1 in drug resistance has been confirmed in lung adenocarcinoma cells, and researchers have discovered that targeting the YB-1/MVP axis may help to overcome gefitinib resistance in lung adenocarcinoma patients [28].